Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
01 2019
Historique:
received: 09 08 2018
revised: 09 10 2018
accepted: 16 10 2018
pubmed: 21 12 2018
medline: 13 2 2020
entrez: 21 12 2018
Statut: ppublish

Résumé

Kabuki syndrome (KS) is an extremely rare genetic disorder, mainly caused by germline mutations at specific epigenetic modifier genes, including KMT2D. Because the tumor suppressor gene KMT2D is also frequently altered in many cancer types, it has been suggested that KS may predispose to the development of cancer. However, KS being a rare disorder, few data are available on the incidence of cancer in KS patients. Here, we report the case of a 5-year-old boy affected by KS who developed Burkitt lymphoma (BL). Genetic analysis revealed the presence of a novel heterozygous mutation in the splice site of the intron 4 of KMT2D gene in both peripheral blood-extracted DNA and tumour cells. In addition, the tumour sample of the patient was positive for the classical somatic chromosomal translocation t(8;14) involving the c-MYC gene frequently identified in BL. We propose that the mutated KMT2D gene contributes to the development of both KS and BL observed in our patient and we suggest that strict surveillance must be performed in KS patients.

Identifiants

pubmed: 30569626
doi: 10.1002/ajmg.a.60674
doi:

Substances chimiques

DNA-Binding Proteins 0
KMT2D protein, human 0
MYC protein, human 0
Neoplasm Proteins 0
Protein Isoforms 0
Proto-Oncogene Proteins c-myc 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113-117

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Emmanuel de Billy (E)

Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.

Luisa Strocchio (L)

Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.

Antonella Cacchione (A)

Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.

Emanuele Agolini (E)

Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, Rome, Italy.

Maria Gnazzo (M)

Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, Rome, Italy.

Antonio Novelli (A)

Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, Rome, Italy.

Rita De Vito (R)

Pathology Unit, Department of Pathology and Molecular Histopathology, Bambino Gesù Children's Hospital, Rome, Italy.

Rossella Capolino (R)

Medical Genetics Unit, Bambino Gesù Children's Hospital, Rome, Italy.

Maria Cristina Digilio (MC)

Medical Genetics Unit, Bambino Gesù Children's Hospital, Rome, Italy.

Roberta Caruso (R)

Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.

Angela Mastronuzzi (A)

Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.

Franco Locatelli (F)

Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.
Department of Pediatric Sciences, University of Pavia, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH